https://www.selleckchem.com/products/Cyt387.html
Therefore, the combination of anti-CD20 and NO donors should result in the inhibition of tumor cell proliferation and the reversal of resistance of B-NHL cells. It is postulated that the combination use of well-designed subtoxic NO donors in combination with anti-CD20 mAbs should result in the improved treatment of patients who are initially unresponsive and/or are refractory to prior treatments.Rituximab, a chimeric mouse/human monoclonal antibody (mAb) targeting CD20, has proven to improve treatment outcomes in a number of B-cell malig
Aimer
Commentaire
Partagez
